These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15865597)

  • 21. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
    Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
    Hamid Z; Simmons DL
    Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
    [No Abstract]   [Full Text] [Related]  

  • 23. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
    Prentice JC; Conlin PR; Gellad WF; Edelman D; Lee TA; Pizer SD
    Value Health; 2014 Dec; 17(8):854-62. PubMed ID: 25498781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
    Komajda M; Curtis P; Hanefeld M; Beck-Nielsen H; Pocock SJ; Zambanini A; Jones NP; Gomis R; Home PD;
    Cardiovasc Diabetol; 2008 Apr; 7():10. PubMed ID: 18435852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
    Hansen RA; Farley JF; Droege M; Maciejewski ML
    Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pioglitazone/metformin (Actoplus met).
    Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
    Ceriani E; Costantino G; Casazza G; Podda GM;
    Lancet; 2010 Oct; 376(9750):1387; author reply 1388. PubMed ID: 20971354
    [No Abstract]   [Full Text] [Related]  

  • 29. Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
    Ferrante G; Zavalloni D; Corrada E; Presbitero P
    Lancet; 2010 Oct; 376(9750):1387-8; author reply 1388. PubMed ID: 20971352
    [No Abstract]   [Full Text] [Related]  

  • 30. [Triple oral therapy in type 2 diabetes].
    Scheen AJ
    Rev Med Suisse; 2005 Aug; 1(30):1942, 1944-6, 1948. PubMed ID: 16200937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Fixed-dose combination].
    Nagai Y
    Nihon Rinsho; 2015 Mar; 73(3):465-9. PubMed ID: 25812374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The UK Prospective Diabetes Study.
    Kerner W
    Lancet; 1998 Dec; 352(9144):1934. PubMed ID: 9863811
    [No Abstract]   [Full Text] [Related]  

  • 34. Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes.
    Asche CV; McAdam-Marx C; Shane-McWhorter L; Sheng X; Plauschinat CA
    Diabetes Obes Metab; 2008 Aug; 10(8):638-45. PubMed ID: 17645555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
    Kahler KH; Rajan M; Rhoads GG; Safford MM; Demissie K; Lu SE; Pogach LM
    Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, effectiveness and safety of sulphonylurea-metformin combination therapy in patients with type 2 diabetes.
    Hermann LS; Lindberg G; Lindblad U; Melander A
    Diabetes Obes Metab; 2002 Sep; 4(5):296-304. PubMed ID: 12190992
    [No Abstract]   [Full Text] [Related]  

  • 37. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
    Hermansen K; Kolotkin RL; Hammer M; Zdravkovic M; Matthews D
    Prim Care Diabetes; 2010 Jul; 4(2):113-7. PubMed ID: 20444662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin initiation in Type 2 diabetes.
    Page S
    Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011
    [No Abstract]   [Full Text] [Related]  

  • 39. Roundtable. Blueprint for conversion of patients on metformin and sulfonylurea to Glucovance.
    Roselli A; Hayes JD; Seidner R; Marchione V; Snyder CM; Mayes K; Stiernberg CM; Milgram L
    Manag Care; 2001 Feb; 10(2 Suppl):17-21. PubMed ID: 11729404
    [No Abstract]   [Full Text] [Related]  

  • 40. Rosiglitazone and cardiotoxicity--weighing the evidence.
    Nathan DM
    N Engl J Med; 2007 Jul; 357(1):64-6. PubMed ID: 17551161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.